 SAN DIEGO, Feb. 04, 2021 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals, Inc. Nasdaq: CRNX, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that CRN04894, the companys lead adrenocorticotropic hormone ACTH antagonist for the treatment of diseases associated with excess ACTH such as Cushings disease and congenital adrenal hyperplasia CAH, has advanced into the clinic. Based on encouraging preclinical results, Crinetics has initiated a double-blind, randomized, placebo-controlled Phase 1 study of this orally administered, nonpeptide small molecule drug candidate in healthy volunteers. This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation. 